melinta_logo
melinta_sub_banner1
melinta_sub_banner2
melinta_sub_banner3
melinta_sub_banner4
melinta_sub_banner5
Video

Acute bacterial skin and skin structure infections are major reasons for hospitalizations in the United States, affecting millions of people annually










Zervos MJ et al, Epidemiology and Outcomes of Complicated Skin and Soft Tissue Infections in Hospitalized Patients. J Clin Microbiol 2012 Feb;50(2):238-45.

Agency for Healthcare Research and Quality, 2011 data (http://hcupnet.ahrq.gov/HCUPnet.jsp)
At least 2 million people in the U.S. acquire serious infections with bacteria that are resistant to one or more of the antibiotics designed to combat them.

More than 23,000 people in the U.S. die each year from antibiotic-resistant infections. Many more die from conditions complicated by an antibiotic-resistant infection.










Source: U.S. Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2013.

Bassetti, M. et al; DELAFLOXACIN FOR THE TREATMENT OF RESPIRATORY AND SKIN INFECTIONS Expert Opinion on Investigational Drugs, Mar 2015, Vol. 24, No. 3: 433–442.

Published March 2015
Click Here to Read Online15



ESKAPE pathogens are the six resistant bacteria that are among the most difficult to treat:


66% of all hospital infections are caused by ESKAPE pathogens.










Source: Rice LB. Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: no ESKAPE. J. Infect. Dis.197(8), 1079-1081 (2008)
Press Releases and News
May 19, 2015
Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients’ Recovery from Acute Bacterial Skin Infections
April 14, 2015
Melinta Therapeutics Announces Publication of an Independent Review of Delafloxacin Clinical Results and Pharmacokinetics
April 9, 2015
Melinta Therapeutics Shows that Health-Related Quality-of-Life is higher in ABSSSI Patients Deemed Cured vs Improved after End of Treatment